Table 2.
Studies implicating macrophage phenotype in non-biomaterial-mediated fibrosis
| Fibrosis Model | Species | Macrophage-associated Experimental Condition | Outcome | Reference | |
|---|---|---|---|---|---|
| M1-associated studies | idopathic pulmonary fibrosis | human | - | ↑ expression of IL1β, collagen type I and III, fibronectin | [99] |
| cardiac fibrosis | murine | IL6 knockout | ↓ expression of αSMA, TGFβ1, collagen | [112] | |
| bleomycin-induced fibrotic legions | murine | STAT3 knockout | ↓ expression of SOCS3, IL10, and decorin. ↑ expression of TGFβ1 | [115] | |
| M2-associated studies | scenescent muscle | murine | - | ↑ collagen, tissue stiffness, ↓ nNOS | [118] |
| scenescent muscle | murine | muscle-specific nNOS transgene | ↓ M2 macrophages and muscle fibrosis in older muscle tissue | [87] | |
| endometriosis | murine (Balb/C) | - | ↓ M2 macrophages (CD163), ↑ collagen, αSMA, SMAD3, and CD41 | [120] | |
| endometriosis | murine (C57BL/6) | macrophage ablation and adoptive transfer of M1, M2a, or M2c macrophages | adoptive transfer of M2a macrophages (MRC1) ⟹ ↑ collagen I, TGFβ1, αSMA compared to M1 (iNOS) or M2c (VTCN1) | [120] | |
| tissue fibrosis | murine | IL4Rα knockout | ↓ M2 markers (CD163, MRC1, PDGFB, IL10) and unchanged M1 markers (IL1β, TNFα, IL) vs. controls. M2a-derived RELMα ⟹ ↑ LH2 in fibroblasts | [124] | |
| fibrotic chronic pancreatitis | murine and human | IL4Rα knockout, macrophage depletion, and IL4/IL13 blocking antibodies | IL4/IL13 blocking ⟹ ↓ M2a macrophages and decrease in fibrosis | [125] | |
| bleomycin-induced lung fibrosis | murine | IL13Rα2 blocking antibody | ↓ TGFβ1 and collagen deposition | [126] | |
| heart-allograft fibrosis | murine | IL13Rα2 blocking via siRNA | fibrosis was prevented | [127] | |
| failing renal allograft | human | - | CD68, aSMA, MRC1 | [129] | |
| renal fibrosis | murine | SMAD3 knockout | macrophage-myofibroblast transition | [130] |